$447.43
0.10% yesterday
Nasdaq, Sep 03, 10:03 pm CET
ISIN
US02043Q1076
Symbol
ALNY

Alnylam Pharmaceuticals, Inc Target price 2025 - Analyst rating & recommendation

Alnylam Pharmaceuticals, Inc Classifications & Recommendation:

Buy
79%
Hold
21%

Alnylam Pharmaceuticals, Inc Price Target

Target Price $457.47
Price $447.43
Potential
Number of Estimates 32
32 Analysts have issued a price target Alnylam Pharmaceuticals, Inc 2026 . The average Alnylam Pharmaceuticals, Inc target price is $457.47. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 39 analysts: 31 Analysts recommend Alnylam Pharmaceuticals, Inc to buy, 8 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Alnylam Pharmaceuticals, Inc stock has an average upside potential 2026 of . Most analysts recommend the Alnylam Pharmaceuticals, Inc stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Billion $ 2.25 3.57
22.97% 58.97%
EBITDA Margin -5.35% 6.26%
57.15% 217.08%
Net Margin -12.37% 3.20%
48.62% 125.86%

35 Analysts have issued a sales forecast Alnylam Pharmaceuticals, Inc 2025 . The average Alnylam Pharmaceuticals, Inc sales estimate is

$3.6b
Unlock
. This is
45.17% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$4.0b 62.88%
Unlock
, the lowest is
$3.3b 34.73%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $2.2b 22.97%
2025
$3.6b 58.97%
Unlock
2026
$5.0b 38.81%
Unlock
2027
$6.3b 27.33%
Unlock
2028
$7.9b 25.31%
Unlock
2029
$9.3b 17.66%
Unlock
2030
$10.3b 10.37%
Unlock
2031
$10.7b 3.97%
Unlock
2032
$11.0b 3.31%
Unlock

13 Analysts have issued an Alnylam Pharmaceuticals, Inc EBITDA forecast 2025. The average Alnylam Pharmaceuticals, Inc EBITDA estimate is

$224m
Unlock
. This is
280.86% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$462m 473.11%
Unlock
, the lowest is
$56.6m 145.80%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $-120m 47.30%
2025
$224m 286.10%
Unlock
2026
$1.1b 390.81%
Unlock
2027
$1.9b 70.67%
Unlock
2028
$6.3b 238.05%
Unlock
2029
$9.2b 45.78%
Unlock
2030
$10.7b 16.35%
Unlock

EBITDA Margin

2024 -5.35% 57.15%
2025
6.26% 217.08%
Unlock
2026
22.13% 253.51%
Unlock
2027
29.67% 34.07%
Unlock
2028
80.03% 169.73%
Unlock
2029
99.15% 23.89%
Unlock
2030
104.52% 5.42%
Unlock

35 Alnylam Pharmaceuticals, Inc Analysts have issued a net profit forecast 2025. The average Alnylam Pharmaceuticals, Inc net profit estimate is

$114m
Unlock
. This is
135.79% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$353m 210.77%
Unlock
, the lowest is
$-271m 15.12%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-278m 36.82%
2025
$114m 141.06%
Unlock
2026
$689m 503.48%
Unlock
2027
$1.4b 105.80%
Unlock
2028
$2.7b 87.27%
Unlock
2029
$3.2b 20.49%
Unlock
2030
$3.8b 17.47%
Unlock
2031
$3.8b 0.33%
Unlock
2032
$4.2b 12.19%
Unlock

Net Margin

2024 -12.37% 48.62%
2025
3.20% 125.86%
Unlock
2026
13.89% 334.06%
Unlock
2027
22.45% 61.63%
Unlock
2028
33.55% 49.44%
Unlock
2029
34.36% 2.41%
Unlock
2030
36.57% 6.43%
Unlock
2031
35.29% 3.50%
Unlock
2032
38.32% 8.59%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -2.18 0.87
38.07% 139.91%
P/E 513.19
EV/Sales 15.90

35 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast for earnings per share. The average Alnylam Pharmaceuticals, Inc EPS is

$0.87
Unlock
. This is
135.66% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$2.70 210.66%
Unlock
, the lowest is
$-2.07 15.16%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.18 38.07%
2025
$0.87 139.91%
Unlock
2026
$5.26 504.60%
Unlock
2027
$10.83 105.89%
Unlock
2028
$20.28 87.26%
Unlock
2029
$24.43 20.46%
Unlock
2030
$28.70 17.48%
Unlock
2031
$28.80 0.35%
Unlock
2032
$32.31 12.19%
Unlock

P/E ratio

Current -183.37 60.21%
2025
513.19 379.86%
Unlock
2026
85.04 83.43%
Unlock
2027
41.32 51.41%
Unlock
2028
22.06 46.61%
Unlock
2029
18.31 17.00%
Unlock
2030
15.59 14.86%
Unlock
2031
15.54 0.32%
Unlock
2032
13.85 10.88%
Unlock

Based on analysts' sales estimates for 2025, the Alnylam Pharmaceuticals, Inc stock is valued at an EV/Sales of

15.90
Unlock
and an P/S ratio of
16.41
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 23.08 68.47%
2025
15.90 31.12%
Unlock
2026
11.45 27.96%
Unlock
2027
8.99 21.47%
Unlock
2028
7.18 20.20%
Unlock
2029
6.10 15.01%
Unlock
2030
5.53 9.40%
Unlock
2031
5.32 3.82%
Unlock
2032
5.15 3.21%
Unlock

P/S ratio

Current 23.82 65.60%
2025
16.41 31.11%
Unlock
2026
11.82 27.96%
Unlock
2027
9.28 21.47%
Unlock
2028
7.41 20.20%
Unlock
2029
6.30 15.01%
Unlock
2030
5.71 9.40%
Unlock
2031
5.49 3.82%
Unlock
2032
5.31 3.21%
Unlock

Current Alnylam Pharmaceuticals, Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
HC Wainwright & Co.
Locked
Locked
Locked Aug 07 2025
JP Morgan
Locked
Locked
Locked Aug 06 2025
Wolfe Research
Locked
Locked
Locked Aug 04 2025
Oppenheimer
Locked
Locked
Locked Aug 04 2025
Chardan Capital
Locked
Locked
Locked Aug 01 2025
Morgan Stanley
Locked
Locked
Locked Aug 01 2025
Canaccord Genuity
Locked
Locked
Locked Aug 01 2025
Analyst Rating Date
Locked
HC Wainwright & Co.:
Locked
Locked
Aug 07 2025
Locked
JP Morgan:
Locked
Locked
Aug 06 2025
Locked
Wolfe Research:
Locked
Locked
Aug 04 2025
Locked
Oppenheimer:
Locked
Locked
Aug 04 2025
Locked
Chardan Capital:
Locked
Locked
Aug 01 2025
Locked
Morgan Stanley:
Locked
Locked
Aug 01 2025
Locked
Canaccord Genuity:
Locked
Locked
Aug 01 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today